Factors associated with genetic testing in a cohort of breast cancer survivors

Abstract

We examined factors associated with self‐reported use of genetic testing among breast cancer survivors based on a 2015 cross‐sectional survey at eight Midwestern sites. Genetic testing was reported in 39% of our 1235 study participants, with higher utilization among those aged <50 and with a triple‐negative cancer. Bilateral mastectomy, having relatives with breast cancer, and younger age were associated with increased genetic testing use. Increasing income, in interaction with age, was associated with use of genetic testing among younger but not older patients. Rural residency emerged as a possible barrier for genetic testing among women with triple‐negative cancer.

Patient perspectives on testing for clonal hematopoiesis of indeterminate potential

“…In the setting of germline genetic testing, higher socioeconomic variables, such as income or education, are associated with an increased interest in and uptake of testing, although reports have not been consistent. 37 , 38 It is possible that within this young and educated cohort, some women may prioritize their health, even in the setting of subjective financial discomfort. Inherited disease-predisposing genetic mutations (ie, BRCA1/2, TP53 ) and CHIP differ significantly in their associated risks, inheritability, and management strategies, and further investigation of the association between socioeconomic factors and CHIP testing is warranted.…”

Histórico familiar para câncer de mama em mulheres: estudo populacional em Uberaba (MG) utilizando o Family History Screen-7

“…Os achados sobre a renda refletem um perfil socioeconômico da amostra classificada com risco familiar pelo FHS-7. Blaes et al 20 relataram maior renda para mulheres com testagem genética positiva para o câncer de mama, o que pode refletir a relação entre renda e maior capacidade de acesso à testagem genética. No entanto, na presente pesquisa, tal análise não foi controlada por outras variáveis que poderiam influenciar esse quadro, como etnia e escolaridade, podendo ser considerada uma limitação da presente pesquisa.…”

Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA

“…Mutations and polymorphisms in them can lead to abnormal cell growth, which can lead to the development of cancer. Among the genes that are associated with the development and progression of breast cancer, the following are currently listed [ 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ]: BRCA1 and BRCA2 genes, which have the best documented association with breast cancer; having a mutation in these genes is responsible for a 50–80% risk of breast cancer and a 45% risk of ovarian cancer before the age of 85—with a mutation in the BRCA1 gene and a 31–56% risk of breast cancer and 11–27% of ovarian cancer in BRCA2 mutation [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]; the PALB2 gene, which is responsible for the repair of damaged DNA; carriers of the defective gene have a 35% risk of developing breast cancer before the age of 70 [ 31 , 32 , 33 , 34 , 35 , 36 ]; the CHEK2 gene, which is responsible for the production of a protein that inhibits tumor growth; women with a mutation in this gene have a twice as high a risk of developing breast cancer compared to the general population [ 37 , 38 , 39 , 40 , 41 , 42 ]; the NBN gene, which encodes a protein regulating the DNA repair process and maintaining chromosome stability [ 43 , 44 , 45 , 46 , ...…”